Cullen Frost Bankers Inc. Sells 11,506 Shares of Medtronic PLC $MDT

Cullen Frost Bankers Inc. lowered its position in shares of Medtronic PLC (NYSE:MDT) by 4.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 265,395 shares of the medical technology company’s stock after selling 11,506 shares during the period. Cullen Frost Bankers Inc.’s holdings in Medtronic were worth $25,276,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC purchased a new position in Medtronic during the 3rd quarter valued at about $27,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic during the 3rd quarter valued at approximately $33,000. Tripletail Wealth Management LLC bought a new position in Medtronic during the 3rd quarter valued at approximately $34,000. Finally, GFG Capital LLC purchased a new stake in Medtronic in the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.4%

Shares of Medtronic stock opened at $100.98 on Friday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The firm has a market cap of $129.45 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 2.66 and a beta of 0.71. The company has a 50-day moving average of $99.44 and a 200 day moving average of $95.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s dividend payout ratio is presently 76.55%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Morgan Stanley upped their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Robert W. Baird set a $103.00 price objective on shares of Medtronic in a research report on Tuesday, December 16th. Sanford C. Bernstein upped their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Jefferies Financial Group reaffirmed a “hold” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Finally, Daiwa Capital Markets increased their price target on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Fourteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).